This program was presented by TIMO in partnership with Society for Immunotherapy of Cancer
May 23-24, 2014
Martin Luther University
Halle-Wittenberg
University Clinic Halle (Saale)
Organizer:
Dr. Barbara Seliger
Friday, May 23, 2014 |
|
Session: Biomarkers and Immune Signature Chair: Zelig Eshhar, Francesco M. Marincola |
|
9:15 am - 9:45 am | Shaping Anti-cancer Immune Response in the Tumor Microenvironment Wolf Fridman (Paris, France) |
9:45 am - 10:15 am | Immunoscore of Tumors Bernard A. Fox, (Portland, OR) |
10:15 am - 10:45 am | Cancer Immunotherapy, Do We Know Who Will Be Benefited? Ena Wang (Doha, Qatar) |
10:45 am - 11:00 am | Signal Computation Downstream of Cytokine and Growth Factor Receptors Stephan Feller (Halle, Germany) |
Session: Immune Escape and Immune Suppression |
|
11:30 am - 12:00 pm | Identification of miRs Involved in Immune Suppression/Activation of Tumors Barbara Seliger (Halle, Germany) |
12:00 pm - 12:30 pm | Conversation of Melanoma Educated Monocytes to MDSC – Like Cells and Their Effect on T Cell Response Rolf Kiessling (Stockholm, Sweden) |
12:30 pm - 1:00 pm | Immunology of Cancer Stem Cells Giorgio Parmiani (Milan – Italy) |
Session: NK Cells and Antitumor Response |
|
1:00 pm - 2:15 pm | The Role of Adhesion in NK Cell Cytotoxicity – A Sticky Business Carsten Watzl (Dortmund, Germany) |
2:15 pm - 2:45 pm | Using NK Cells to Treat Human Hematopoetic Malignancies Hans-Gustaf Ljunggren (Stockholm – Sweden) |
2:45 pm - 3:15 pm | Harnessing Natural Killer Cells Against Cancer Adelheid Cerwenka (Heidelberg – Germany) |
Session: Novel Immunotherapeutic Strategies |
|
3:35 pm - 4:15 pm | CARs and Pancreatic Carcinoma Zelig Eshhar (Israel - I) |
4:15 pm - 4:45 pm | TCR Gene Therapy: Improving Safety and Efficiency Wolfgang Uckert (Berlin, Germany) |
4:45 pm - 5:15 pm | Improvement of Adoptive T Cell Therapy in Melanoma: Challenges and Future NN (Herlev, Denmark) |
Saturday, May 24, 2014 |
|
Session: Immunotherapies and Targeted Therapies Chair: Patrick Hwu / Laurence Zitvogel |
|
8:30 am - 9:00 am | DC Therapy - Where Do We Go From Here? Gerold Schuler (Erlangen – Germany) |
9:00 am - 9:30 am | Immunotherapy of Pancreatic Cancer: The Need for Powerful Approaches Rienk Offringa (Heidelberg, Germany) |
9:30 am - 10:00 am | Novel Therapy Approaches Based on Specific siRNA Delivery and DNA Methyltransferase Inhibition Carsten Müller-Tidow (Halle, Germany) |
10:00 am - 10:30 am | Immune Checkpoint Antibodies: Clinical Trials and Biomarkers Michele Maio (Siena, Italy) |
Session: Immunotherapies and Targeted Therapies |
|
11:00 am - 11:30 am | Role of IL-2 Ra / L-2RY and IL-2 on the Efficacy of Anti-CTLA4 Treatment: Predictor of Response to Therapy Laurence Zitvogel (Villejuif, France) |
11:30 am - 12:00 pm | The Use of the PD-1 Abrogating Antibody Nivolumab and Biomarkers for Its Efficacy in Melanoma Jeffrey Weber (Tampa, FL) |
12:00 pm - 12:30 pm | TBA Patrick Hwu (Houston, TX) |
For more information please email: sylvi.magdeburg©uk-halle.de